Professor John Barrett, a renowned nephrologist from the University of Leicester, discusses the latest advancements in the treatment of IgA nephropathy. Filmed at the 61st ERA Conference in Stockholm, he highlights the explosion of clinical trials and new drugs that are revolutionizing the management of this chronic kidney disease. Professor Barrett explains the significance of early changes in proteinuria as a key indicator of drug efficacy and the promising new therapies targeting both the production of pathogenic IgA and inflammation within the kidney. He also touches on the future potential of various treatments in improving patient outcomes.